Northwestern University purchased a new stake in Actuate Therapeutics (NASDAQ:ACTU – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 27,778 shares of the company’s stock, valued at approximately $207,000. Actuate Therapeutics makes up 0.2% of Northwestern University’s investment portfolio, making the stock its 5th biggest holding. Northwestern University owned about 0.14% of Actuate Therapeutics at the end of the most recent quarter.
Separately, KG&L Capital Management LLC purchased a new stake in Actuate Therapeutics in the 3rd quarter worth approximately $89,000.
Actuate Therapeutics Trading Down 0.7 %
Actuate Therapeutics stock opened at $8.94 on Friday. Actuate Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $10.16. The stock has a fifty day moving average price of $7.91.
Actuate Therapeutics Profile
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
See Also
- Five stocks we like better than Actuate Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Tesla Investors Continue to Profit From the Trump Trade
- Following Congress Stock Trades
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- The 3 Best Blue-Chip Stocks to Buy Now
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Want to see what other hedge funds are holding ACTU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Actuate Therapeutics (NASDAQ:ACTU – Free Report).
Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.